Verteporfin is a medicine used to treat a specific type of age-related vision loss called wet macular degeneration. It works by stopping abnormal blood vessel growth in the retina. This helps to protect your vision. It's given as an injection into the eye.
Every report comes from a Lived member, sent anonymously.
Have you tried Verteporfin for Central Serous Chorioretinopathy?
Verteporfin, sold as Visudyne, is a light-activated medicine used in photodynamic therapy (PDT) for certain diseases at the back of the eye. In the US it is approved to treat abnormal blood vessels that grow beneath the macula, the small central part of the retina responsible for sharp, detailed vision. Doctors call this choroidal neovascularization (CNV). These fragile vessels leak fluid and blood, which can blur or distort central vision quickly. The approval covers a specific pattern of CNV (described as predominantly classic) caused by wet age-related macular degeneration (AMD), severe nearsightedness (pathologic myopia) or presumed ocular histoplasmosis, an eye complication of an earlier fungal infection. For most people with wet AMD, eye injections that block VEGF (vascular endothelial growth factor, a signal that drives abnormal vessel growth) are now the usual first choice, because they preserved vision better than verteporfin in a head-to-head trial. Verteporfin remains useful in selected situations, alone or alongside those injections. Retina specialists also use it off-label (outside the approved uses) for polypoidal choroidal vasculopathy, a form of wet AMD with bulging, polyp-like vessels; for central serous chorioretinopathy, in which fluid collects under the retina; and for choroidal hemangioma, a noncancerous blood vessel tumor at the back of the eye.
Verteporfin does very little on its own until light switches it on. After it is infused into a vein, it travels in the bloodstream and tends to collect in abnormal new blood vessels. The eye doctor then shines a low-power red laser onto the affected area of the retina. The light activates the drug, which reacts with oxygen to produce short-lived, highly reactive molecules that damage the inner lining of those vessels. Small clots form, the vessels close, and leakage slows or stops. The laser does not heat or burn the retina; its job is only to activate the drug in the targeted spot. Even so, some surrounding retinal tissue can be affected. The vessel closure is often temporary, which is why the eye is rechecked and treatment is sometimes repeated.
Verteporfin is given only in an eye specialist's clinic, as a two-step treatment on the same visit. First, the medicine runs into an arm vein through an IV over 10 minutes. The dose is calculated from body surface area, which is based on height and weight. About 15 minutes after the infusion starts, the doctor applies the laser to the eye for roughly a minute and a half while you sit at a slit lamp (the microscope used for eye exams), with a magnifying lens held against the eye. For central serous chorioretinopathy, specialists often use a reduced dose of the drug or a reduced amount of laser light to lower the chance of retinal side effects. The clinic will usually give you a reminder, such as a wristband, about the light precautions that follow, so it helps to bring dark sunglasses and clothing that covers your skin for the trip home.
The most common side effects are reactions where the IV went in (pain, swelling, bruising or discoloration) and changes in vision such as blurring, flashes of light, reduced sharpness or blind spots. Each affects roughly 10 to 30 percent of people. Back pain during the infusion is also fairly common and mainly occurs while the drug is running in. Skin exposed to sunlight in the first few days can develop a sunburn-like reaction. If the drug leaks out of the vein into the surrounding tissue, it can cause severe pain, swelling and even skin damage, especially if that area is then exposed to light. Tell the staff right away if the IV site hurts or swells; they will stop the infusion, and the area needs to be kept covered from light until the swelling and discoloration fade. In about 1 to 5 percent of people, vision in the treated eye drops sharply within a week of treatment, sometimes with only partial recovery. Contact the eye doctor promptly if this happens; it also affects decisions about further treatment. Severe allergic reactions, fainting and chest pain during the infusion are rare, which is one reason the infusion is supervised. If trouble breathing, swelling of the face or throat, or fainting begins after you leave the clinic, call 911.
Verteporfin must not be used by people with porphyria, a group of inherited disorders that cause extreme sensitivity to light, or by anyone who has had an allergic reaction to it. The central warning is light sensitivity. For 5 days after treatment, the drug remaining in the skin and eyes can react to light and cause burns. During that time, avoid direct sunlight and bright indoor light, including tanning beds, halogen lamps and the strong lights used in operating rooms and dental offices; prolonged use of light-emitting devices such as a finger pulse oximeter should also be avoided. Sunscreen does not protect, because visible light, not just ultraviolet light, activates the drug. If you must go outside in daylight, cover all skin and wear dark sunglasses. Staying in a dark room is not recommended either: ordinary indoor light gradually breaks down the leftover drug in the skin. If emergency surgery is needed within 48 hours, the surgical team should know about the treatment. Other medicines that make skin more sensitive to sunlight could add to this effect. Examples include tetracycline antibiotics, sulfa antibiotics, thiazide diuretics (water pills used for blood pressure), sulfonylurea diabetes pills and phenothiazines (a group of antipsychotic and anti-nausea medicines). Formal drug interaction studies have not been done, so the care team should see a full list of medicines and supplements. There are no human data on use in pregnancy, and very high doses harmed unborn rats, so it is used during pregnancy only when the benefit clearly justifies the risk. Verteporfin passes into breast milk; people who are breastfeeding should decide with their doctor whether to pause nursing or postpone treatment.
Plan for someone else to drive you home. Vision is often blurry or dim for a while after treatment, and you should not drive or operate machinery until it clears. The 5 days of light precautions are the main disruption to daily life, so it helps to schedule treatment around a period when you can stay mostly indoors. The goal is to stop leakage and protect the vision you still have; it generally does not bring back vision already lost. In the trials behind its approval for wet AMD, about two-thirds of treated people avoided moderate vision loss (losing 3 or more lines on an eye chart) after a year, compared with about 40 percent of people given a sham treatment. When verteporfin is combined with anti-VEGF injections for polypoidal choroidal vasculopathy, studies suggest better vision and fewer injections than either treatment alone. The eye doctor usually rechecks the eye about every 3 months, often with fluorescein angiography (photographs taken after a dye is injected to show leaking vessels), and repeats treatment if leakage continues. Some people need several treatments, more often in the first year. In recent years, worldwide supply problems have at times delayed verteporfin treatment, so ask about availability if timing matters.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Verteporfin, what you've noticed, or ask the community a question.